Lilly trial slowdown could include Phase III GI candidate; Syncona among others acknowledging delays

Lilly’s decision to delay most clinical trial starts and suspend enrollment in most ongoing trials makes it the latest and largest biopharma to acknowledge a broad impact of the COVID-19 outbreak on its development plans for therapeutic candidates.

The decision won’t affect most of the late-stage trials in progress for Eli Lilly and Co. (NYSE:LLY); however, the company said it could adjust timelines for Phase III studies of mirikizumab to treat gastrointestinal indications. Lilly said its 2020 financial guidance is unaffected at this point...